Ascletis Pharma Inc.
ASCLF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $2 | $1 | $4 | $0 |
| - Cash | $1 | $0 | $2 | $2 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $1 | $1 | $2 | -$2 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -97.7% | 4.6% | -29.6% | – |
| Gross Profit | $0 | $0 | -$0 | $0 |
| % Margin | 57.3% | 45.9% | -45.6% | 51% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -30,432.6% | -222.8% | -526% | -220.3% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -23,455.7% | -255.7% | -582.1% | -258.9% |
| EPS Diluted | -0.3 | -0.13 | -0.29 | -0.18 |
| % Growth | -130.8% | 55.2% | -61.1% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |